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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 36
th
 prioritisation (May 2018), 12 drugs were filtered out of 404 identified and were sent to 
prioritisation. Of these, 7 drugs were ranked as ‘highly relevant’ by the expert panel, 5 as ‘relevant’ 
and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, 
abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
No Filtered Drugs – 36
th prioritisation 3rd quarter 2018 Overall category 
1. 
Apalutamide (Erleada
®
) treatment and metastasis-free survival in 
prostate cancer 
Highly relevant 
2. 
Dacomitinib versus gefitinib as first-line treatment for patients with 
EGFR-mutation-positive non-small-cell lung cancer (NSCLC) 
Relevant 
3. 
Nivolumab (Opdivo
®
) plus ipilimumab in lung cancer with a high 
tumor mutational burden 
Highly relevant 
4. 
Pembrolizumab (Keytruda
®
) plus chemotherapy in metastatic 
NSCLC 
Highly relevant 
5. 
Dual human epidermal growth factor receptor 2 (HER2) blockade 
with lapatinib (Tyverb
®
) plus trastuzumab in combination with an 
aromatase inhibitor in postmenopausal women with HER2-positive, 
hormone receptor-positive metastatic breast cancer 
Relevant 
6. 
Addition of the PARP inhibitor veliparib plus carboplatin or 
carboplatin alone to standard neoadjuvant chemotherapy in triple-
negative breast cancer 
Relevant 
7. 
Blinatumomab (Blincyto
®
) for minimal residual disease (MRD) in 
adults with B-cell precursor acute lymphoblastic leukaemia (ALL) 
Highly relevant 
8. 
Venetoclax (Venclyxto
®
, Venclexta
®
) plus rituximab in relapsed or 
refractory chronic lymphocytic leukemia (CLL) 
Highly relevant 
9. 
Encorafenib (LGX818) plus binimetinib versus vemurafenib or 
encorafenib in patients with BRAF-mutant melanoma 
Relevant 
10. 
Adjuvant pembrolizumab (Keytruda
®
) versus placebo in resected 
stage III melanoma 
Highly relevant 
11. 
Nivolumab (Opdivo
®
) plus ipilimumab versus sunitinib in advanced 
renal cell carcinoma (RCC) 
Highly relevant 
12. 
S-1 (Teysuno
®
) and irinotecan plus bevacizumab versus 
mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in 
patients with metastatic colorectal cancer (mCRC) 
Relevant 
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1 Prostate Cancer 
1.1 Apalutamide (Erleada®) treatment and metastasis-free survival 
in prostate cancer 
Overview 
Drug Description a competitive inhibitor of the androgen receptor 
Patient Indication 
patients with nonmetastatic castration-resistant prostate cancer who are at 
high risk for the development of metastasis 
Incidence in 
Austria 
4,854 newly diagnosed per year (2015), 130.6/100,000 men/year 
(European Standard Population, 2013) 
Ongoing Phase III 
 
NCT01946204 (SPARTAN) ongoing until August 2019 
NCT02489318 until July 2022 
NCT02257736 until August 2021 
 
Approval 
status for 
this 
indication 
EMA - 
FDA 
02/2018: the FDA approved apalutamide for patients with non-metastatic 
castration-resistant prostate cancer  
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
Phase III results 
NEJM; available online February 8, 2018 (Smith et al.): “Apalutamide treatment and metastasis-free 
survival in prostate cancer”   
 
Background 
Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment 
of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-
resistant prostate cancer who were at high risk for the development of metastasis. 
Methods 
We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic 
castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. 
Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. 
All the patients continued to receive androgen-deprivation therapy. The primary end point was 
metastasis-free survival, which was defined as the time from randomization to the first detection of 
distant metastasis on imaging or death. 
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Results 
A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo 
group). In the planned primary analysis, which was performed after 378 events had occurred, median 
metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in 
the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 
0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with 
placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to 
discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo 
group. The following adverse events occurred at a higher rate with apalutamide than with placebo: 
rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%). 
Conclusion 
Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time 
to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by 
Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204.) 
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2 Lung Cancer 
2.1 Nivolumab (Opdivo®) plus ipilimumab in lung cancer with a 
high tumor mutational burden 
Overview 
Drug Description 
 
nivolumab is a programmed death 1 (PD-1) immune checkpoint inhibitor 
antibody  
 
Patient Indication 
 
patients with squamous or nonsquamous stage IV or recurrent NSCLC 
who had received no previous systemic anticancer therapy as primary 
therapy for advanced or metastatic disease  
 
Incidence in 
Austria 
 
4,860 newly diagnosed per year (2015), 57.9/100,000 persons/year 
(European Standard Population, 2013), including lung, trachea and 
bronchial tumours 
 
Ongoing Phase III 
 
NCT02477826 (CheckMate 227) ongoing until 12/2020 
NCT03469960 until 04/2023 
NCT02998528 until 11/2028 
NCT02864251 until 12/2023 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
 
approved indications (product information, updated 05/2018): 
- as monotherapy or in combination with ipilimumab for the 
treatment of advanced (unresectable or metastatic) melanoma in 
adults 
- as monotherapy for the treatment of locally advanced or 
metastatic non-small cell lung cancer after prior chemotherapy in 
adults 
- as monotherapy for the treatment of advanced RCC after prior 
therapy in adults  
- as monotherapy for the treatment of adult patients with relapsed or 
refractory classical Hodgkin lymphoma after autologous stem cell 
transplant (ASCT) and treatment with brentuximab vedotin 
- as monotherapy for the treatment of squamous cell cancer of the 
head and neck in adults progressing on or after platinum-based 
therapy  
- as monotherapy for the treatment of locally advanced 
unresectable or metastatic urothelial carcinoma in adults after 
failure of prior platinum-containing therapy.  
 
FDA 
 
approved indications (label information 04/2018) for the treatment of: 
- patients with BRAF V600 wild-type unresectable or metastatic 
melanoma, as a single agent  
- patients with BRAF V600 mutation-positive unresectable or 
metastatic melanoma, as a single agent (accelerated approval) 
- patients with unresectable or metastatic melanoma, in 
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combination with ipilimumab (accelerated approval) 
- patients with melanoma with lymph node involvement or 
metastatic disease who have undergone complete resection, in 
the adjuvant setting.  
- patients with metastatic non-small cell lung cancer and progres 
sion on or after platinum-based chemotherapy; patients with 
EGFR or ALK genomic tumor aberrations should have disease 
progression on FDA-approved therapy for these aberrations prior 
to receiving nivolumab  
- patients with advanced renal cell carcinoma who have received 
prior anti-angiogenic therapy in patients with intermediate or poor 
risk, previously untreated advanced renal cell carcinoma, in 
combination with ipilimumab 
- adult patients with classical Hodgkin lymphoma that has relapsed 
or progressed after (accelerated approval) autologous 
hematopoietic stem cell transplantation (HSCT) and  
brentuximab vedotin, or 3 or more lines of systemic therapy that 
includes autologous HSCT  
- patients with recurrent or metastatic squamous cell carcinoma of 
the head and neck with disease progression on or after platinum-
based therapy  
- patients with locally advanced or metastatic urothelial carcinoma 
who (accelerated approval) have disease progression during or 
following platinum-containing chemotherapy or have disease 
progression within 12 months of neoadjuvant or adjuvant 
treatment with platinum-containing chemotherapy 
- adult and pediatric (12 years and older) patients with microsatellite  
instability-high (MSI-H) or mismatch repair deficient (dMMR) 
metastatic colorectal cancer that has progressed following 
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan 
(accelerated approval) 
- patients with hepatocellular carcinoma who have been previously 
treated with sorafenib (accelerated approval). 
 
Costs  
 
One vial of 4 mL contains 40 mg of nivolumab = € 572.00  
one vial of 10 mL contains 100 mg of nivolumab = € 1,430.00 (ex-factory 
prices) 
CheckMate 224 patients received either chemotherapy, nivolumab 3 
mg/kg of body weight every 2 weeks = 240 mg* = € 3,432.00/dose) + 
ipilimumab or nivolumab monotherapy (240 mg every 2 weeks). Trial 
patients received a median number of 9 nivolumab doses (combination 
therapy with ipilimumab)  -> € 30,888.00 
 
*assuming a body weight of 80 kg 
Phase III results 
NEJM; available online April 16, 2018 (Hellmann et al.): “Nivolumab plus ipilimumab in lung cancer 
with a high tumor mutational burden” 
Background  
Nivolumab plus ipilimumab showed promising efficacy for the treatment of non– small-cell lung cancer 
(NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of 
benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival 
with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational 
burden (≥10 mutations per megabase). 
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Methods  
We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with 
chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 
1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab 
monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were 
randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus 
chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne 
CDx assay. 
 
Findings  
Progression-free survival among patients with a high tumor mutational burden was significantly longer 
with nivolumab plus ipilimumab than with chemotherapy. The 1-year progression-free survival rate was 
42.6% with nivolumab plus ipilimumab versus 13.2% with chemotherapy, and the median progression-
free survival was 7.2 months (95% confidence interval [CI], 5.5 to 13.2) versus 5.5 months (95% CI, 
4.4 to 5.8) (hazard ratio for disease progression or death, 0.58; 97.5% CI, 0.41 to 0.81; P<0.001). The 
objective response rate was 45.3% with nivolumab plus ipilimumab and 26.9% with chemotherapy. 
The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within 
subgroups, including patients with a PD-L1 expression level of at least 1% and those with a level of 
less than 1%. The rate of grade 3 or 4 treatment-related adverse events was 31.2% with nivolumab 
plus ipilimumab and 36.1% with chemotherapy. 
 
Interpretation  
Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with 
chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 
expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role 
of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and 
Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.) 
 
 
2.2 Pembrolizumab (Keytruda®) plus chemotherapy in metastatic 
NSCLC 
Overview 
Drug Description a programmed death 1 (PD-1) inhibitor 
Patient Indication 
 
Patients with metastatic nonsquamous NSCLC without sensitizing EGFR 
or ALK mutations who had received no previous systemic therapy for 
metastatic disease 
 
Incidence in 
Austria 
 
4,860 newly diagnosed per year (2015), 57.9/100,000 persons/year 
(European Standard Population, 2013), including lung, trachea and 
bronchial tumours 
 
Ongoing Phase III 
 
NCT02578680 (KEYNOTE-189) ongoing until 01/2020 
NCT02142738 until 05/2019 
NCT02220894 until 01/2020 
NCT03322566 until 12/2022 
 
Approval 
status for 
this 
indication 
EMA -  
FDA -  
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Approval 
status for 
other 
indications 
EMA 
 
according to product information (updated 04/2018), pembrolizumab is 
indicated: 
- as monotherapy for the treatment of advanced (unresectable or 
metastatic) melanoma in adults 
- as monotherapy for the first-line treatment of metastatic non-small 
cell lung carcinoma (NSCLC) in adults whose tumours express 
PD-L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR 
or ALK positive tumour mutations 
- as monotherapy for the treatment of locally advanced or 
metastatic NSCLC in adults whose tumours express PD-L1 with a 
≥ 1% TPS and who have received at least one prior chemotherapy 
regimen; patients with EGFR or ALK positive tumour mutations 
should also have received targeted therapy before receiving 
pembrolizumab 
- as monotherapy for the treatment of adult patients with relapsed or  
refractory classical Hodgkin lymphoma (cHL) who have failed 
autologous stem cell transplant (ASCT) and brentuximab vedotin 
(BV), or who are transplant -ineligible and have failed BV 
- as monotherapy for the treatment of locally advanced or 
metastatic urothelial carcinoma in adults who have received prior 
platinum -containing chemotherapy  
- as monotherapy for the treatment of locally advanced or 
metastatic urothelial carcinoma in adults who are not eligible for 
cisplatin -containing chemotherapy. 
-  
FDA 
 
According to label information (11/2017), pembrolizumab is indicated: 
- for  the treatment of patients with unresectable or metastatic 
melanoma 
- as a single agent for the first-line treatment of patients with 
metastatic NSCLC whose tumors have high PD -L1 expression 
[(Tumor Proportion Score (TPS) ≥50%)] as determined by an 
FDA-approved test, with no EGFR or ALK genomic tumor 
aberrations 
- as a single agent for the treatment of patients with metastatic 
NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined 
by an FDA-approved test, with disease progression on or after 
platinum-containing chemotherapy; patients with EGFR or ALK 
genomic tumor aberrations should have disease progression on  
FDA -approved therapy for these aberrations prior to receiving 
pembrolizumab  
- in combination with pemetrexed and carboplatin, as first-line 
treatment of patients with metastatic nonsquamous NSCLC 
(accelerated approval)  
- for the treatment of patients with recurrent or metastatic head and 
neck squamous cell cancer (HNSCC) with disease progression on 
or after platinum-containing chemotherapy (accelerated approval) 
- for the treatment of adult and pediatric patients with refractory 
classical Hodgkin lymphoma (cHL), or who have relapsed after 3 
or more prior lines of therapy (accelerated approval) 
- for the treatment of patients with locally advanced or metastatic  
urothelial carcinoma who are not eligible for cisplatin-containing 
chemotherapy (accelerated approval) 
- for the treatment of patients with locally advanced or metastatic 
urothelial carcinoma who have disease progression during or 
following platinum-containing chemotherapy or within 12 months 
of neoadjuvant or adjuvant treatment with platinum-containing 
chemotherapy 
- for the treatment of adult and pediatric patients with unresectable 
or metastatic, microsatellite instability-high (MSI-H) or mismatch 
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repair deficient solid tumors that have progressed following prior 
treatment and who have no satisfactory alternative treatment 
options, or colorectal cancer that has progressed following 
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan 
(accelerated approval). Limitation of Use: The safety and 
effectiveness of pembrolizumab in pediatric patients with MSI-H 
central nervous system cancers have not been established 
- for the treatment of patients with recurrent locally advanced or 
metastatic gastric or gastroesophageal junction adenocarcinoma 
whose tumors express PD-L1 [Combined Positive Score (CPS) 
≥1] as determined by an FDA-approved test, with disease 
progression on or after two or more prior lines of therapy including 
fluoropyrimidine- and platinum-containing chemotherapy and if 
appropriate, HER2/neu-targeted therapy (accelerated approval). 
 
Costs  
 
Keytruda
®
 50 mg powder for concentrate for solution for infusion = € 
1,714.00 (ex-factory price).  
KEYNOTE – 189 – patients received pemetrexed and a platinum-based 
drug plus either 200 mg (€ 6,856.00 per dose) of pembrolizumab (or 
placebo every 3 weeks for 4 cycles, followed by pembrolizumab or 
placebo for up to a total of 35 cycles plus pemetrexed maintenance 
therapy. 
 
Phase III results 
NEJM; available online 16 April, 2018 (Gandhi et al.): “Pembrolizumab plus chemotherapy in 
metastatic non–small-cell lung cancer” 
Background 
First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is 
platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death 
ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-
line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly 
higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 
trial. 
 
Methods  
In this double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) 616 patients with metastatic 
nonsquamous NSCLC without sensitizing EGFR or ALK mutations who had received no previous 
treatment for metastatic disease to receive pemetrexed and a platinum-based drug plus either 200 mg 
of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up 
to a total of 35 cycles plus pemetrexed maintenance therapy. Crossover to pembrolizumab 
monotherapy was permitted among the patients in the placebo-combination group who had verified 
disease progression. The primary end points were overall survival and progression-free survival, as 
assessed by blinded, independent central radiologic review. 
 
Findings  
After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 
69.2% (95% confidence interval [CI], 64.1 to 73.8) in the pembrolizumab- combination group versus 
49.4% (95% CI, 42.1 to 56.2) in the placebo-combination group (hazard ratio for death, 0.49; 95% CI, 
0.38 to 0.64; P<0.001). Improvement in overall survival was seen across all PD-L1 categories that 
were evaluated. Median progression-free survival was 8.8 months (95% CI, 7.6 to 9.2) in the 
pembrolizumab-combination group and 4.9 months (95% CI, 4.7 to 5.5) in the placebo-combination 
group (hazard ratio for disease progression or death, 0.52; 95% CI, 0.43 to 0.64; P<0.001). Adverse 
events of grade 3 or higher occurred in 67.2% of the patients in the pembrolizumab-combination group 
and in 65.8% of those in the placebo-combination group. 
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Interpretation  
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK 
mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-
based drug resulted in significantly longer overall survival and progression-free survival than 
chemotherapy alone. (Funded by Merck; KEYNOTE-189 ClinicalTrials.gov number, NCT02578680.) 
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3 Leukaemia 
3.1 Blinatumomab (Blincyto®) for minimal residual disease (MRD) 
in adults with B-cell precursor acute lymphoblastic leukaemia 
(ALL) 
Overview 
Drug Description 
 
a bispecific T cell–engager antibody construct that directs T cells to CD19
+
 
cells 
 
Patient Indication 
 
patients with B-cell precursor ALL in first or later haematologic complete 
remission (CR) and with persistent or recurrent MRD ≥ 10
-3
 after a 
minimum of 3 blocks of intensive chemotherapy. 
 
Incidence in 
Austria 
 
ALL total incidence rate: 1.1/100,000/year  
 
Ongoing Phase III 
 
NCT01207388 (BLAST) ongoing until 01/2019 
NCT03476239 until 11/2021 
NCT02101853 until 03/2022 
NCT02393859 until 12/2022 
 
Approval 
status for 
this 
indication 
EMA 
 
07/2009: orphan designation was granted for blinatumomab for the 
treatment of ALL 
 
11/2015: approved for the treatment of adults with Philadelphia 
chromosome negative relapsed or refractory B-precursor ALL 
 
FDA 
 
12/2014: indicated for treatment of Philadelphia chromosomenegative 
relapsed or refractory B-cell precursor ALL 
 
03/2018: indicated for the treatment of adults and children with B-cell 
precursor ALL in first or second CR with MRD greater than or equal to 
0.1% (accelerated approval)  
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs  
 
Blincyto
® 38.5 micrograms powder for concentrate and solution for 
infusion, one vial = € 2826.08 (ex-factory price). 
 
BLAST-trial: patients received 15 μg/m
2
/day (IV) of blinatumumab for 4 
weeks, followed by 2 treatment-free weeks (=1 cycle). 1 dose = 25.95 
μg/day. Costs for one cycle = € 84,782.4.  
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Phase III results 
Blood Journal (2018); 131(14):1522-1531 Gökbuget N et al.: “Blinatumomab for minimal residual 
disease in adults with B-cell precursor acute lymphoblastic leukemia” 
Background  
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete 
remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase–
polymerase chain reaction or flow cytometry.MRD is the strongest predictor of relapse in ALL. 
 
Methods  
In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete 
remission with MRD (≥ 10
-3
) received blinatumomab 15 μg/m2 per day by continuous IV infusion for up 
to 4 cycles. Patients could undergo allogeneic hematopoietic stem-cell transplantation any time after 
cycle 1. The primary end point was complete MRD response status after 1 cycle of blinatumomab. 
 
Findings  
One hundred sixteen patients received blinatumomab. Eighty-eight (78%) of 113 evaluable patients 
achieved a complete MRD response. In the subgroup of 110 patients with Ph-negative ALL in 
hematologic remission, the Kaplan- Meier estimate of relapse-free survival (RFS) at 18 months was 
54%. Median overall survival (OS) was 36.5 months. In landmark analyses, complete MRD 
responders had longer RFS (23.6 vs. 5.7 months; P = .002) and OS (38.9 vs. 12.5 months; P = .002) 
compared with MRD nonresponders. Adverse events were consistent with previous studies of 
blinatumomab. Twelve (10%) and 3 patients (3%) had grade 3 or 4 neurologic events, respectively. 
Four patients (3%) had cytokine release syndrome grade 1, n 5 2; grade 3, n 5 2), all during cycle 1. 
 
Interpretation  
After treatment with blinatumomab in a population of patients with MRD-positive B-cell precursor ALL, 
a majority achieved a complete MRD response, which was associated with significantly longer RFS 
and OS compared with MRD nonresponders. This study is registered at www.clinicaltrials.gov as 
#NCT01207388. (Blood. 2018;131(14):1522-1531). 
 
 
3.2 Venetoclax (Venclyxto®, Venclexta®) plus rituximab in relapsed 
or refractory chronic lymphocytic leukemia (CLL) 
Overview 
Drug Description 
 
an inhibitor of BCL2, an antiapoptotic protein that is pathologically 
overexpressed and that is central to the survival of chronic lymphocytic 
leukemia cells 
 
Patient Indication 
 
Patients with relapsed or refractory CLL that required therapy; and had 
received one to three previous treatments (including at least one 
chemotherapy- containing regimen) 
 
Incidence in 
Austria 
 
7.4/100,000 men/year, 4.8/100,000 women/year (2011) 
 
Ongoing Phase III NCT02005471 ongoing until 09/2018 
Approval 
status for 
this 
indication 
EMA 
 
orphan designation was granted for the treatment of CLL (12/2012), for the 
treatment of acute myeloid leukaemia (02/2016), for the treatment of 
diffuse large B-cell carcinoma and multiple myeloma (10/2016) and for the 
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treatment of mantle cell lymphoma (12/2017) 
10/2016: venetoclax monotherapy is indicated for the treatment of chronic 
lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 
mutation in adult patients who are unsuitable for or have failed a B cell 
receptor pathway inhibitor. Venetoclax monotherapy is indicated for the 
treatment of CLL in the absence of 17p deletion or TP53 mutation in adult 
patients who have failed both chemoimmunotherapy and a B cell receptor 
pathway inhibitor  
FDA 
 
04/2016:  indicated for the treatment of patients with chronic lymphocytic 
leukemia (CLL) with 17p deletion as detected by an FDA approved test 
who have received at least one prior therapy (accelerated approval) 
 
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs  
 
10 Venclyxto
®
 tablets á 10 mg = € 53.53 (ex-factory price) 
14 Venclyxto
®
 tablets á 100 mg = € 749.38 (ex-factory price) 
 
Trial patients received venetoclax according to a 5-week schedule of a 
gradual increase in the dose from 20 mg per day to 400 mg per day. 
 
Phase III results 
NEJM;378:1107-20; 2018 (Seymour et al): “Venetoclax–rituximab in relapsed or refractory chronic 
lymphocytic leukemia” 
Background  
Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is 
central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in 
combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. 
 
Methods  
In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax 
for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax–rituximab 
group) or bendamustine plus rituximab for 6 months (bendamustine–rituximab group). The trial design 
did not include crossover to venetoclax plus rituximab for patients in the bendamustine–rituximab 
group in whom progression occurred. The primary end point was investigator-assessed progression-
free survival. 
 
Findings  
After a median follow-up period of 23.8 months, the rate of investigator-assessed progression-free 
survival was significantly higher in the venetoclax–rituximab group (32 events of progression or death 
in 194 patients) than in the bendamustine–rituximab group (114 events in 195 patients); the 2-year 
rates of progression-free survival were 84.9% and 36.3%, respectively (hazard ratio for progression or 
death, 0.17; 95% confidence interval [CI], 0.11 to 0.25; P<0.001 by the stratified log-rank test). The 
benefit was maintained across all clinical and biologic subgroups, including the subgroup of patients 
with chromosome 17p deletion; the 2-year rate of progression-free survival among patients with 
chromosome 17p deletion was 81.5% in the venetoclax–rituximab group versus 27.8% in the 
bendamustine–rituximab group (hazard ratio, 0.13; 95% CI, 0.05 to 0.29), and the 2-year rate among 
those without chromosome 17p deletion was 85.9% versus 41.0% (hazard ratio, 0.19; 95% CI, 0.12 to 
0.32). The benefit of venetoclax plus rituximab over bendamustine plus rituximab was confirmed by an 
independent review committee assessment of progression-free survival and other secondary efficacy 
end points. The rate of grade 3 or 4 neutropenia was higher in the venetoclax– rituximab group than in 
the bendamustine–rituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or 
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infestations were lower with venetoclax than with bendamustine. The rate of grade 3 or 4 tumor lysis 
syndrome in the venetoclax– rituximab group was 3.1% (6 of 194 patients). 
 
Interpretation  
Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab 
resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. 
(Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471.) 
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4 Melanoma 
4.1 Adjuvant pembrolizumab (Keytruda®) versus placebo in 
resected stage III melanoma 
Overview 
Drug Description a programmed death 1 (PD-1) inhibitor 
Patient Indication 
 
patients with cutaneous melanoma with metastasis to regional lymph 
nodes; the patients had to have either stage IIIA melanoma (patients with 
stage N1a melanoma had to have at least one micrometastasis measuring 
>1 mm in greatest diameter) or stage IIIB or IIIC disease with no in-transit 
metastases  
 
Incidence in 
Austria 
 
1,779 newly diagnosed per year (2015), 20.7/100,000 persons/year 
(European Standard Population, 2013) 
 
Ongoing Phase III 
 
NCT02362594 (Keynote-054) ongoing until 07/2025 
NCT02506153 until 09/2023 
 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
 
according to product information (updated 04/2018), pembrolizumab is 
indicated: 
- as monotherapy for the treatment of advanced (unresectable or 
metastatic) melanoma in adults 
- as monotherapy for the first-line treatment of metastatic non-small 
cell lung carcinoma (NSCLC) in adults whose tumours express 
PD-L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR 
or ALK positive tumour mutations 
- as monotherapy for the treatment of locally advanced or 
metastatic NSCLC in adults whose tumours express PD-L1 with a 
≥ 1% TPS and who have received at least one prior chemotherapy 
regimen; patients with EGFR or ALK positive tumour mutations 
should also have received targeted therapy before receiving 
pembrolizumab 
- as monotherapy for the treatment of adult patients with relapsed or  
refractory classical Hodgkin lymphoma (cHL) who have failed 
autologous stem cell transplant (ASCT) and brentuximab vedotin 
(BV), or who are transplant -ineligible and have failed BV 
- as monotherapy for the treatment of locally advanced or 
metastatic urothelial carcinoma in adults who have received prior 
platinum -containing chemotherapy  
- as monotherapy for the treatment of locally advanced or 
metastatic urothelial carcinoma in adults who are not eligible for 
cisplatin -containing chemotherapy 
FDA 
 
according to label information (11/2017), pembrolizumab is indicated: 
- for  the treatment of patients with unresectable or metastatic 
melanoma 
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- as a single agent for the first-line treatment of patients with 
metastatic NSCLC whose tumors have high PD -L1 expression 
[(Tumor Proportion Score (TPS) ≥50%)] as determined by an 
FDA-approved test, with no EGFR or ALK genomic tumor 
aberrations 
- as a single agent for the treatment of patients with metastatic 
NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined 
by an FDA-approved test, with disease progression on or after 
platinum-containing chemotherapy; patients with EGFR or ALK 
genomic tumor aberrations should have disease progression on  
FDA -approved therapy for these aberrations prior to receiving 
pembrolizumab  
- in combination with pemetrexed and carboplatin, as first-line 
treatment of patients with metastatic nonsquamous NSCLC 
(accelerated approval)  
- for the treatment of patients with recurrent or metastatic head and 
neck squamous cell cancer (HNSCC) with disease progression on 
or after platinum-containing chemotherapy (accelerated approval) 
- for the treatment of adult and pediatric patients with refractory 
classical Hodgkin lymphoma (cHL), or who have relapsed after 3 
or more prior lines of therapy (accelerated approval) 
- for the treatment of patients with locally advanced or metastatic  
urothelial carcinoma who are not eligible for cisplatin-containing 
chemotherapy (accelerated approval) 
- for the treatment of patients with locally advanced or metastatic 
urothelial carcinoma who have disease progression during or 
following platinum-containing chemotherapy or within 12 months 
of neoadjuvant or adjuvant treatment with platinum-containing 
chemotherapy 
- for the treatment of adult and pediatric patients with unresectable 
or metastatic, microsatellite instability-high (MSI-H) or mismatch 
repair deficient solid tumors that have progressed following prior 
treatment and who have no satisfactory alternative treatment 
options, or colorectal cancer that has progressed following 
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan 
(accelerated approval). Limitation of Use: The safety and 
effectiveness of pembrolizumab in pediatric patients with MSI-H 
central nervous system cancers have not been established 
- for the treatment of patients with recurrent locally advanced or 
metastatic gastric or gastroesophageal junction adenocarcinoma 
whose tumors express PD-L1 [Combined Positive Score (CPS) 
≥1] as determined by an FDA-approved test, with disease 
progression on or after two or more prior lines of therapy including 
fluoropyrimidine- and platinum-containing chemotherapy and if 
appropriate, HER2/neu-targeted therapy (accelerated approval). 
 
Costs  
 
Keytruda
®
 50 mg powder for concentrate for solution for infusion = € 
1,714.00 (ex-factory price).  
Trial patients received either 200 mg (€ 6,856.00/ per dose) of 
pembrolizumab or placebo intravenously every 3 weeks for a total of 18 
doses (€ 123,408.00/18 doses) 
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Phase III results 
NEJM; available online 15 April, 2018 (Eggermont et al.): “Adjuvant pembrolizumab versus placebo 
in resected stage III melanoma” 
Background  
The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free 
and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind 
trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III 
melanoma. 
 
Methods  
Patients with completely resected stage III melanoma were randomly assigned (with stratification 
according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) 
or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or 
until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall 
intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 
ligand (PD-L1) were the primary end points. Safety was also evaluated. 
 
Findings  
At a median follow-up of 15 months, pembrolizumab was associated with significantly longer 
recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of 
recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 
65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup 
of 853 patients with PD-L1–positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 
72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; 
hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related 
to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of 
patients in the placebo group. There was one treatment-related death due to myositis in the 
pembrolizumab group. 
 
Interpretation  
As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 
weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no 
new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594; EudraCT 
number, 2014-004944-37.) 
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5 Kidney Cancer 
5.1 Nivolumab (Opdivo®) plus ipilimumab versus sunitinib in 
advanced renal cell carcinoma (RCC) 
Overview 
Drug Description 
 
nivolumab is a programmed death 1 (PD-1) immune checkpoint inhibitor 
antibody  
 
Patient Indication 
 
patients with previously untreated advanced renal-cell carcinoma 
with a clear-cell component 
 
Incidence in 
Austria 
 
kidney cancer: 1,258 newly diagnosed per year (2015), 14.8/100,000 
persons/year (European Standard Population, 2013); approx. 80% of all 
kidney cancers are RCCs  
 
Ongoing Phase III 
 
NCT02231749 (CheckMate 214) ongoing until 09/2019 
NCT03138512 until 07/2023 
NCT01668784 until 09/2018 
NCT03141177 until 04/2023 
 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
 
approved indications (product information, updated 05/2018): 
- as monotherapy or in combination with ipilimumab for the 
treatment of advanced (unresectable or metastatic) melanoma in 
adults 
- as monotherapy for the treatment of locally advanced or 
metastatic non-small cell lung cancer after prior chemotherapy in 
adults 
- as monotherapy for the treatment of advanced RCC after prior 
therapy in adults  
- as monotherapy for the treatment of adult patients with relapsed or 
refractory classical Hodgkin lymphoma after autologous stem cell 
transplant (ASCT) and treatment with brentuximab vedotin 
- as monotherapy for the treatment of squamous cell cancer of the 
head and neck in adults progressing on or after platinum-based 
therapy  
- as monotherapy for the treatment of locally advanced 
unresectable or metastatic urothelial carcinoma in adults after 
failure of prior platinum-containing therapy.  
 
FDA 
 
approved indications (label information 04/2018) for the treatment of: 
- patients with BRAF V600 wild-type unresectable or metastatic 
melanoma, as a single agent  
- patients with BRAF V600 mutation-positive unresectable or 
metastatic melanoma, as a single agent (accelerated approval) 
- patients with unresectable or metastatic melanoma, in combinati 
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on with ipilimumab (accelerated approval) 
- patients with melanoma with lymph node involvement or 
metastatic disease who have undergone complete resection, in 
the adjuvant setting.  
- patients with metastatic non-small cell lung cancer and progres 
sion on or after platinum-based chemotherapy; patients with 
EGFR or ALK genomic tumor aberrations should have disease 
progression on FDA-approved therapy for these aberrations prior 
to receiving nivolumab  
- patients with advanced renal cell carcinoma who have received 
prior anti-angiogenic therapy in patients with intermediate or poor 
risk, previously untreated advanced renal cell carcinoma, in 
combination with ipilimumab 
- adult patients with classical Hodgkin lymphoma that has relapsed 
or progressed after (accelerated approval) autologous 
hematopoietic stem cell transplantation (HSCT) and  
brentuximab vedotin, or 3 or more lines of systemic therapy that 
includes autologous HSCT  
- patients with recurrent or metastatic squamous cell carcinoma of 
the head and neck with disease progression on or after platinum-
based therapy  
- patients with locally advanced or metastatic urothelial carcino 
- ma who (accelerated approval) have disease progression during 
or following platinum-containing chemotherapy or have disease 
progression within 12 months of neoadjuvant or adjuvant 
treatment with platinum-containing chemotherapy 
- adult and pediatric (12 years and older) patients with microsatellite  
instability-high (MSI-H) or mismatch repair deficient (dMMR) 
metastatic colorectal cancer that has progressed following 
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan 
(accelerated approval) 
- patients with hepatocellular carcinoma who have been previously 
treated with sorafenib (accelerated approval). 
 
Costs  
 
One vial of 4 mL contains 40 mg of nivolumab = € 572.00 
one vial of 10 mL contains 100 mg of nivolumab = € 1,430.00 (ex-factory 
prices) 
CheckMate 214 – patients received 3 mg/kg of body weight (240 mg* 
nivolumab per dose/ € 3,432.00) IV every 3 weeks for 4 doses (induction 
phase) and 3 mg/kg of body weight every 2 weeks (maintenance phase). 
Median treatment duration in the CheckMate trial was 7.9 months (approx. 
14 doses of nivolumab costing ~ € 48,048.  
 
*assuming a body weight of 80 kg 
Phase III results 
NEJM; available online 21 March 2018 (Motzer et al.): “Nivolumab plus ipilimumab versus sunitinib 
in advanced renal-cell carcinoma” 
Background  
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell 
carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for 
previously untreated clear-cell advanced renal-cell carcinoma. 
 
Methods  
We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body 
weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by 
nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-
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week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response 
rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with 
intermediate or poor prognostic risk. 
 
Findings  
A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib 
(546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 
months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% 
confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with 
sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 
months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% 
versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-
free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or 
death, 0.82; P = 0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse 
events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 
patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 
patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 
22% and 12% of the patients in the respective groups. 
 
Interpretation  
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab 
than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced 
renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 
ClinicalTrials.gov number, NCT02231749.) 
 
 
